Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is an aggressive hematologic malignancy originating from immature plasmacytoid dendritic cell (PDC) precursors. The initial manifestation of BPDCN often consists of cutaneous lesions. In this educational article, the clinical, histologic and therapeutic aspects of BPDCN are discussed from a dermatologic perspective.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Psoriasis: intervening in the inflammatory cascade
Advantages of early biologic therapy and oral peptide as a beacon of hope
- AI-supported imaging and new biomarkers
CHD diagnostics update
- Bipolar disorder, anxiety disorder, depression
Lurasidone as monotherapy for bipolar I depression with anxiety symptoms
- Arterial hypertension: ESC guideline 2024 in focus
New category “elevated blood pressure” – what are the therapeutic implications?
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Low-grade pediatric gliomas
Consideration of the tumor microenvironment opens up new treatment options
- Patient-centered rounds in medicine
Aligning care with the patient
- HIV: antiretroviral therapy (ART)